EQS-Adhoc: Termination of the botulinum toxin project

EQS-Ad-hoc: HAEMATO AG / Key word(s): Strategic Company Decision
Termination of the botulinum toxin project

15-Nov-2023 / 19:42 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out.  After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the project for a proprietary botulinum toxin. This decision has no impact on the company's operating business.

About :
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de.



Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.ag


End of Inside Information

15-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English Company: HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany Phone: +49 (0)30 897 30 86 70 Fax: +49 (0)30 897 30 86 79 E-mail: ir@haemato.ag Internet: www.haemato.ag ISIN: DE000A289VV1 WKN: A289VV Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange EQS News ID: 1774581
  End of Announcement EQS News Service

1774581  15-Nov-2023 CET/CEST